68-2

38/110

1) Johnson RW, Dworkin RH: Treatment of herpes zoster and postherpetic neuralgia. BMJ, 2003; 326: 748-750. 2) Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA: Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella- zoster virus. Antimicrob Agents Chemother, 1992; 36: 2747-2757. 3) Kamiyama T, Kurokawa M, Shiraki K: Characteriza-tion of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol, 2001; 82: 2761-2765. 4) Chono K, Katsumata K, Suzuki H, Shiraki K: Syner-gistic activity of amenamevir (ASP2151) with nucleo-side analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res, 2013; 97: 154-160. 5) Ono F, Yasumoto S, Furumura M, et al: Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol, 2012; 39: 902-908. 6) Kawashima M, Nemoto O, Honda M, et al: Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclo-vir-controlled phase 3 study. J Dermatol, 2017; 44: 1219-1227. 7) Petersen KL, Rowbotham MC: Natural history of sensory function after herpes zoster. Pain, 2010; 150: 83-92. 8) Drolet M, Levin MJ, Schmader KE, et al: Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine, 2012; 30: 2047-2050. 9) Kramer S, Baeumler P, Geber C, et al: Somatosensory profiles in acute herpes zoster and predictors of posth-erpetic neuralgia. Pain, 2019; 160: 882-894.10) Degreef H, Famciclovir Herpes Zoster Clinical Study Group: Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficiency and safety in the treatment of uncompli-cated herpes zoster in immunocompetent patients. Int J Antimicrob Agents, 1994; 4: 241-246.11) Wood MJ, Shukla S, Fiddian AP, Crooks RJ: Treatment of acute herpes zoster : effect of early (<48h) versus late (48-72h) therapy with acyclovir and valaciclovir 130on prolonged pain. J Infect Dis, 1998; 178: S81-84.12) Higa K, Mori M, Hirata K, Hori K, Manabe H, Dan K: Severity of skin lesions of herpes zoster at the worst phase rather than age and involved region most influ-ences the duration of acute herpetic pain. Pain, 1997; 69: 245-253.13) Jung BF, Johnson RW, Griffin David RJ, Dworkin RH: Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology, 2004; 62: 1545-1551.14) Johnson RW, Rice Andrew SC: Clinical practice. Posth-erpetic neuralgia. N Eng J Med, 2014; 371: 1526-1533.15) Sato K, Adachi K, Nakamura H, et al: Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study. J Dermatol, 2017; 44: 414-422.16) Jeon YH: Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment. Korean J Pain, 2015; 28: 177-184.17) Boyd MR, Bacon TH, Sutton D, Cole M: Antiherpes-virus activity of 9-(4-hydroxy-3-hydroxy-methylbut- 1-yl)guanine(BRL39123) in cell culture. Antimicrob Agents Chemother, 1987; 31: 1238-1242.18) Bacon TH: Famciclovir, from the bench to the patient— a comprehensive review of preclinical data. Int J Anti-microb Agents, 1996; 7: 119-134.19) Crumpacker CS, Schaffer PA: New anti-HSV thera-peutics target the helicase-primase complex. Nat Med, 2002; 8: 327-328.20) Chono K, Katsumata K, Kontani T, et al: ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus type1 and 2. J Antimicrob Chemother, 2010; 65: 1733-1741.21) Yajima M, Yamada H, Takemoto M, et al: Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor. Antiviral Res, 2017; 139: 95-101.22) Coen PG, Scott F, Leedham-Green M, et al: Predicting and preventing post-herpetic neuralgia: Are current risk factors useful in clinical practice? Eur J Pain, 2006; 10: 695-700.23) Koga R, Yamada K, Ishikawa R, Kubota Y, Yamaguchi K, Iseki M: Association between treatment-related early changes in psychological factors and develop-ment of postherpetic neuralgia. J Anesth, 2019; 33: 636-641.24) Wang XX, Zhang Y, Fan BF: Predicting Postherpetic Neuralgia in Patients with Herpes Zoster by Machine Learning: A Retrospective Study. Pain Ther, 2020; 9: 627-635.Conflicts of interest statementThe authors declare that there are no conflicts of interest.References